Sugi Predict

Sugi Predict / Compounds / SCHEMBL18264342

SCHEMBL18264342

SCHEMBL18264342

CCC(O)c1ccc(Cl)cn1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ APLNR P35414 1/20 0.39
▸ ESR1 P03372 4/20 0.39
▸ ESR2 Q92731 4/20 0.39
▸ PTK2 Q05397 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ADRA2A P08913 1/20 0.36
▸ ADRA2B P18089 1/20 0.36
▸ ADRA2C P18825 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18264361 1.00 TSHR (0.40) TSHRBRD4L3MBTL1MAPK1APLNR
SCHEMBL29108562 0.84 PYGL (0.46) BRD4L3MBTL1APLNRADRA2AADRA2B
SCHEMBL20832725 0.84 BRD4 (0.37) BRD4L3MBTL1MAPK1APLNRADRA2A
SCHEMBL30640205 0.84 PYGL (0.46) BRD4L3MBTL1APLNRADRA2AADRA2B
SCHEMBL30640220 0.84 PYGL (0.46) BRD4L3MBTL1APLNRADRA2AADRA2B
SCHEMBL24501187 0.84 PYGL (0.46) BRD4L3MBTL1APLNRADRA2AADRA2B
SCHEMBL29108209 0.84 PYGL (0.46) BRD4L3MBTL1APLNRADRA2AADRA2B
SCHEMBL20832723 0.84 BRD4 (0.37) BRD4L3MBTL1MAPK1APLNRADRA2A
SCHEMBL17611046 0.82 MAOB (0.40) TSHRBRD4L3MBTL1MAPK1APLNR
SCHEMBL21014315 0.82 ESR1 (0.46) TSHRL3MBTL1MAPK1APLNRESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025030002-A2 DGK TARGETING COMPOUNDS AND USES THEREOF ARVINAS OPERATIONS, INC. (US) 2025-02-06 — — WO disclosed
CN-107646034-B 3- (6-chloro-3-oxo-3, 4-dihydro- (2H) -1, 4-benzoxazin-4-yl) propionic acid derivatives or their use as KMO inhibitors 爱丁堡大学理事会 2021-06-15 — — CN disclosed
US-10611756-B2 Method of treating pancreatitis using 1,4-benzoxazine derivatives THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2020-04-07 — — US disclosed
US-10611756-B2 Method of treating pancreatitis using 1,4-benzoxazine derivatives THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2020-04-07 — — US disclosed
US-20190169178-A1 METHODS DR. FALK PHARMA GMBH (DE) 2019-06-06 — — US disclosed
US-20190169178-A1 METHODS DR. FALK PHARMA GMBH (DE) 2019-06-06 — — US disclosed
US-10246447-B2 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-02 — — US disclosed
US-10246447-B2 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-02 — — US disclosed
US-20180170920-A1 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS DR. FALK PHARMA GMBH (DE) 2018-06-21 — — US disclosed
US-20180170920-A1 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS DR. FALK PHARMA GMBH (DE) 2018-06-21 — — US disclosed
US-20180170920-A1 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS DR. FALK PHARMA GMBH (DE) 2018-06-21 — — US disclosed
EP-3298009-A1 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2018-03-28 — — EP disclosed
WO-2016188827-A1 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-12-01 — — WO disclosed
WO-2016188827-A1 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10611756-B2 Method of treating pancreatitis using 1,4-benzoxazine derivatives AMY2A, KMO, KLK5 TSHR 2621/4885BRD4 324/4885L3MBTL1 4605/4885
US-10246447-B2 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors KMO, SNCA, AP1S1 TSHR 1898/4885BRD4 1045/4885L3MBTL1 185/4885
US-20180170920-A1 3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS KMO, SNCA, AP1S1 TSHR 1898/4885BRD4 1045/4885L3MBTL1 185/4885
US-20190169178-A1 METHODS KMO, AMY2A, RNASE1 TSHR 3252/4885BRD4 1321/4885L3MBTL1 4579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.